Oxygen Therapy in Myocardial Infarction Patients With or Without Diabetes: A Predefined Subgroup Analysis From the DETO2X-AMI Trial.
Thomas NyströmStefan K JamesBertil LindahlOllie ÖstlundDavid ErlingeJohan HerlitzElmir OmerovicLinda MellbinJoakim AlfredssonOle FröbertTomas JernbergRobin Hofmannnull nullPublished in: Diabetes care (2019)
Despite markedly higher event rates in patients with MI and diabetes, oxygen therapy did not significantly affect 1-year all-cause death, cardiovascular death, or rehospitalization with MI or HF, irrespective of underlying diabetes, in line with the results of the entire study.
Keyphrases
- type diabetes
- cardiovascular disease
- glycemic control
- heart failure
- phase iii
- acute myocardial infarction
- clinical trial
- study protocol
- stem cells
- phase ii
- cell therapy
- metabolic syndrome
- adipose tissue
- coronary artery disease
- acute coronary syndrome
- skeletal muscle
- insulin resistance
- open label
- atrial fibrillation
- acute heart failure
- replacement therapy
- double blind